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Two groups of esterases react with organophosphorus (OP) compounds: serine esterases
and phosphoric triester hydrolases (PTHs; EC 3.1.8). The acute toxicity of OP compounds
is primarily due to inhibition of acetylcholinesterase (AChE; EC 3.1.1.7). The delayed
polyneuropathy, induced by some OP compounds, is related to the inhibition of the
neuropathy target esterase (NTE). So far, NTE has not been classified in the Enzyme
Nomenclature (1). AChE and NTE are both serine esterases. Unlike serine esterases, OP
compounds are not inhibitors, but substrates of phosphoric triester hydrolases (PTHs):
paraoxonase (PON; EC 3.1.8.1) and DFPase (EC 3.1.8.2). The products of hydrolysis of
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The structural formulae of several OP compounds are given in Figure 1. Sarin, soman,
tabun, and VX are nerve agents. Paraoxon and DFP are characteristic substrates of the
PTHs. Both serine esterases and PTHs react with OP compounds on the same ester or
anhydride bond marked in the figure by an undulated line.
For detailed information, readers are invited to consult books and conference
proceedings listed in references 2-12 at the end of this brief review. Reference 13
summarises the early literature on the subject. Individual papers are not quoted in the text,
because their number would grossly exceed the length of the review.
REACTIONS OF OP COMPOUNDS WITH SERINE ESTERASES
Figure 2 shows the reactions of serine esterases with OP compounds. The inhibition of
serine esterases is due to phosphorylation of the active-site serine. This reaction proceeds
via an intermediate Michaelis-type complex between the enzyme and OP. The
Figure 1 Structural formulae of several organophosphorus compounds
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phosphorylated enzyme (EP) is catalytically inactive. Dephosphorylation with water
(spontaneous reactivation) is very slow, while it is faster with oximes (oxime reactivation).
Depending on the substituents on the phosphorus, EP can undergo dealkylation, which is
termed ageing. An aged enzyme cannot be reactivated.
Figure 2 Reactions of serine esterases with organophosphorus compounds
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Acetylcholinesterase is a globular protein and its three-dimensional structure is known.
Its physiological substrate is acetylcholine. Figure 3 shows a schematic drawing of AChE
molecule. The active site of AChE is in the centre of the molecule, accessible through a
narrow gorge lined with water molecules. The catalytic triad (serine, histidine and glutamic
acid), a choline-binding pocket, and an acyl-binding pocket form the active site.
Furthermore, AChE has an allosteric site close to the rim of the gorge. The allosteric site
is catalytically inactive. However, reversible binding of substrates or other ligands to that
site affects catalysis in the active site. The effect is usually inhibitory. There is some evidence
that the AChE molecule might have a “back door” through which products of substrate
hydrolysis leave the enzyme.
Figure 3 Schematic drawing of the acetylcholinesterase molecule
(prepared by Zoran RadiÊ, UCSD, USA)
Research on AChE is now directed towards identification of individual amino acids
which participate in the individual steps of catalysis. The experimental approach consists
of preparing site-directed mutants, correlating the catalytic properties with the structure
of the mutant and modelling the enzyme/ligand complexes. The results are expected to
further elucidate the mechanism of action of AChE. This, in turn, might facilitate a more
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rational design of compounds which would prevent phosphorylation of the active site by
OPs, facilitate reactivation of EP and slow down ageing. The toxicity of OPs is primarily
determined by these three reactions.
NTE has only recently been cloned and shown to be unrelated to any known serine
hydrolases. Its physiological role is not known. The OP compounds are inhibitors of NTE,
but only some OPs cause delayed polyneuropathy. These OPs phosphorylate the active-
site serine, which, in turn, is followed by ageing of the inhibited NTE. Polyneuropathy does
not develop if ageing does not occur. This could indicate that the axonal maintenance is
sensitive to the negative charge on the aged NTE (Figure 2) and not to the activity of NTE.
Phosphorylation and ageing of NTE occur within minutes, but degeneration of the long
axons takes weeks to develop.
Present studies aim at clarifying the link between NTE and the OP-induced delayed
polyneuropathy. Studies are focused on the molecular structure of NTE and on compounds
which promote OP-induced polyneuropathy without causing polyneuropathy themselves.
The promoters known so far are NTE inhibitors, but it seems unlikely that NTE is the
target enzyme.
HYDROLYSIS OF OP COMPOUNDS BY PHOSPHORIC TRIESTER
HYDROLASES
The mechanism of reaction of OP compounds with PTHs is different from the reaction of
OPs with serine esterases. The molecular structure of PTHs is also different. Phosphoric
triester hydrolases require divalent cations for catalysis as shown in Figure 4. The cation
(M++ in Figure 4) is embedded in histidine residues and binds the water molecule required
for OP hydrolysis. So far, nothing is known about the intermediate steps leading to
hydrolysis, except for the kinetic evidence that a Michaelis complex is formed between
the enzyme and OP. The physiological role of PTHs is also not known.
Figure 4 Reactions of phosphoric triester hydrolases with
organophosphorus compounds
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Phosphoric triester hydrolases hydrolyse a broad range of OP compounds. The
substrate specificities of paraoxonase and DFPase are different, and the same holds for
the cation required for catalysis. Paraoxonase in mammalian sera requires calcium ions,
while DFPase in microorganisms usually depends on magnesium, zinc, or manganese
cations. Recently DFPase was also found in plants and its activity was stimulated by
manganese ions. Phosphoric triester hydrolases are stereoselective like AChE. The OP
enantiomer which is more quickly hydrolysed by PTHs is less inhibitory for AChE, and
vice versa. Phosphoric triester hydrolases have recently been shown to hydrolyse carboxylic
acid esters such as phenylacetate, which is a characteristic substrate of arylesterases (EC
3.1.1.2) (1).
The search for natural substrate(s) and the physiological role of PTHs continues.
Mammalian serum paraoxonases seem to act against cellular damage from toxic agents
and oxidised lipids, and there are some indications that human serum paraoxonases might
be markers of lipid metabolism disorders. The polymorphism of these enzymes in human
sera is well established. Phosphoric triester hydrolases have recently been cloned and
mutants prepared. This has greatly enhanced studies on substrate specificity and
mechanism of substrate hydrolysis. The in vivo role of PTHs in detoxification of OPs and
their use in decontamination from OPs constitutes a very lively field of research.
OXIMES AS ANTIDOTES AND PROTECTORS AGAINST OP COMPOUNDS
The primary mechanism of action of oximes as antidotes is to reactivate the phosphorylated
AChE (Figure 2). The pyridinium oximes PAM-2 and HI-6 (Figure 5) and the bis-pyridinium
dioxime toxogononin are therapeutic drugs in OP poisoning. Not a single oxime prepared
so far is active against a very broad range of OPs. Moreover, none has been known to act
against all four nerve agents. The search for better antidotes is still based on the trial-and-
error approach. The same applies to oximes and other compounds used as prophylactic
agents. Imidazolium oximes, and more recently quinuclidinium derivatives, are under
evaluation. Two compounds from those groups are shown in Figure 5.
The product of dephosphorylation by oximes is the phosphorylated oxime (Figure 2).
Phosphorylated oximes are potent AChE inhibitors, but as they are very unstable,
phosphorylation of the reactivated AChE by phosphorylated oximes has seldom been
reported.
Oximes themselves are also toxic. They bind to AChE as reversible inhibitors.
Reversible inhibitors form complexes with AChE either in the active site or in the allosteric
site or in both sites of the enzyme. Reversible inhibitors, including oximes, protect AChE
from phosphorylation. When the reversible inhibitor binds to the active site, the protection
is due to direct competition between the OP and reversible inhibitor. Binding of a reversible
inhibitor to the allosteric site induces indirect protection of the active site. This has been
well documented by in vitro studies, but was less evaluated in experimental toxicology so
far.
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Figure 5 Structural formulae of several oximes
ESTERASES AS ANTIDOTES, PROTECTORS AND DECONTAMINATING
AGENTS AGAINST OP COMPOUNDS
Phosphorylation of serine esterases by OP compounds occurs on a 1:1 molar basis. This
reaction inhibits the enzyme, but detoxifies OP. Phosphorylation of AChE causes toxicity,
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because phosphorylated AChE cannot hydrolyse its physiological substrate acetylcholine.
On the other hand, butyrylcholinesterase (BChE; EC 3.1.1.8) and carboxylesterase (EC
3.1.1.1) in mammalian sera and tissues can be almost completely inhibited without an
apparent toxic effect. This means that cholinesterases and carboxylesterases act as
scavengers of OPs. However, once phosphorylated, the enzymes cannot detoxify another
OP molecule unless there are oximes which would reactivate the enzyme. Consequently,
cholinesterases and carboxylesterases act as stoichiometric scavengers, while combined
with oximes they become catalytic scavengers.
The feasibility of using serine esterases such as AChE and BChE combined with
oximes as drugs against OPs has been demonstrated in rodents and in non-human primates.
Protein engineering techniques have now enabled an intensive search for enzyme mutants
which, ideally, should meet the requirement to react rapidly with OPs, to age slowly, and
to be easily reactivated by oximes.
PTHs also play a major role in the detoxification of OPs. The high toxicity of OPs for
avian species has been attributed to the low activity of endogenous PTHs. Rabbits, which
have a very high paraoxonase activity, are more resistant to paraoxon than other species.
Human serum paraoxonases exhibit a substrate-dependent polymorphism, with low and
high activity modes for each substrate. Analysis of polymorphisms in population groups
is suggested to identify individuals at risk. Studies on rodents have shown that administration
of purified paraoxonase significantly reduces the toxicity of paraoxon and other OPs. These
promising results stimulate present research on the use of PTHs and their mutants as
drugs against OPs.
Finally, the use of esterases is suggested for the decontamination of skin, clothing
and equipment. PTH from a microorganism immobilised on cotton wipes detoxifies nerve
agents and OP pesticides. Purified AChE or BChE immobilised on polyurethane sponge
do the same. Rinsing the sponge with oxime solutions restores the enzyme activity.
Phosphoric triester hydrolases can be co-immobilised on the same sponge, increasing the
capacity of decontamination. Enzymes immobilised on matrices are more stable than in
solution, and can be used repeatedly.
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Saæetak
ORGANOFOSFORNI SPOJEVI I ESTERAZE: STANJE SADA©NJIH
ISTRAÆIVANJA TOKSI»NOSTI I ZA©TITE OD ORGANOFOSFATA
U ovom prikazu opisane su reakcije organofosfornih (OP) spojeva s kolinesterazama, hidrolazama fosfornih triestera (PTH) i
esterazom koja je povezana s neuropatskim djelovanjem OP spojeva (NTE). Kolinesteraze i NTE su serinske esteraze.
Organofosforni spojevi inhibiraju te enzime zato πto fosforiliraju serin u aktivnom mjestu enzima. Inhibicija acetilkolinesteraze
(AChE) je glavni uzrok akutne  toksiËnosti OP spojeva. Suprotno serinskim esterazama, PTH enzimi hidroliziraju OP spojeve i time
ih detoksiciraju. Oksimi su antidoti kod akutnog otrovanja OP spojevima zato πto defosforiliraju inhibiranu AChE. Oksimi dodatno
πtite slobodnu AChE od fosforiliranja. Hidrolaze fosfornih triestera, kao i butirilkolinesteraza (BChE), sluæe i za dekontaminaciju od
OP spojeva, a oba enzima istraæuju se i kao moguÊi protektori protiv otrovanja OP spojevima. U prikazu su opisane i molekulske
strukture AChE i PTH.
KljuËne rijeËi:
acetilkolinesteraza, butirilkolinesteraza, DFP-aza, esteraze fosfornih triestera, kolinesteraze, oksimi, paraoksonaza, serinske
esteraze
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